Search Results

July 2022 "Today we are celebrating ten years of Exscientia! Founded as a spinout from the University of Dundee on 20 July 2012, Exscientia pioneered the design of We’re excited about delivering the next ten years of Exscientia and advancing AI to design better drugs

January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer, She will maintain both of these roles, in addition to her role at Exscientia.

January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia $5.2 billion in total milestones plus tiered royalties PARIS & OXFORD, England & BOSTON--Sanofi and Exscientia The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel

Richard is the architect behind nearly all of Exscientia's partnerships and collaborations across pharma

Industry News Professor Dame Carol Robinson Received 2023 ASMS John.B.Fenn Award Exscientia Announces Expansion of its Precision Oncology Pipeline Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR Fast Company has named Exscientia as one of the Most Innovative Companies

Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis Exscientia Andrew Hopkins, Exscientia's CEO, will speak at the University of Chicago's Distinguished Seminar Series

Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins Professor Andrew Hopkins, Exscientia £10m in next-generation drug development company OMass Therapeutics Sosei Heptares 2022 ESG report Exscientia

discovery platform Antiverse identifies therapeutic antibodies targeting GPCRs CEO Andrew Hopkins on Exscientias to Modern Drug Discovery Arcoscreen will present in the start-up village at Future Labs Live Basel Exscientia

Molecular Insights into GPCR Function Structural perspectives on chemokine receptors Industry News Exscientia

Inhibition With ICB May Be Needed to Reactivate Antitumor Immune Response Garry Pairaudeau, CTO of Exscientia

News X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market Andrew Hopkins, Exscientia

Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732 Exscientia

Industry News Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development

Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress Parker Moss to Join Exscientia

Industry News Exscientia Initiates Prospective Observational Study in Ovarian Cancer.

Groundbreaking Advancements at ESMO 2023 Novo Nordisk to Buy Hypertension Treatment from KBP Biosciences Exscientia

Industry insights:  Biopharma returns to MC4R; Recursion completes Exscientia acquisition, signaling

, GPCRs, and more Current strategic trends in drug discovery: the present as prologue Industry News Exscientia

Exscientia is the Sniper of the AI Drug Discovery Industry Indivior Announces Q2/H1 2023 Financial Results

Exscientia Business and Financial Update for the Full Year 2022.

Provides Program Update Septerna sells GPCR program to Vertex for $48 million Merck KGgA collaborates with Exscientia

it the right data Inversago Pharma divulges new cannabinoid CB1 receptor antagonists BenevolentAI, Exscientia

disorders Superluminal Medicines Launches to Drug Protein Conformations in a Flash Andrew Hopkins, Exscientia's

Integrating Enhanced Sampling Molecular Dynamics Simulations and Markov State Models Industry News Exscientia

Honoris Causa from the Université de Montpellier Domain Therapeutics presented 3 posters at AACR 2023 Exscientia

Function Characterizing conformational states in GPCR structures using machine learning Industry News Exscientia

Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones Recursion and Exscientia

for detecting peptide variants The Galien Foundation Announces 2023 Prix Galien UK Award Candidates Exscientia

Industry News Addex Announces Upcoming Conferences It Will Participate For H1 2023 Learn more about Exscientia

membrane proteins in collaboration with AstraZeneca Expansion of precision oncology pipeline announced by Exscientia